Monte Rosa Therapeutics, Inc. GLUE
11.77
0.05
0.43%
as of 25 Sep
- Market cap
- $999.9M
- P/E
- 0.0×
Follow GLUE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
23.16 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.36 | 10.53 | 38.25 | 85.49 | |
P/FCF ratio |
4.21 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
6.08 | (30.28) | (43.97) | (55.67) | |
P/B ratio |
2.48 | 5.59 | 3.15 | 5.04 | |
Price to Tangible BV |
2.48 | 5.59 | 3.15 | 5.04 | |
EV/Sales |
1.21 | 7.48 | 22.74 | 63.87 | |
EV/EBITDA |
13.02 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
1.47 | (40.59) | (66.57) | (76.23) | |
EV/FCF |
1.51 | (33.66) | (49.70) | (57.19) | |
Quick Ratio |
6.45 | 6.05 | 9.44 | 10.49 | |
Current Ratio |
6.54 | 6.12 | 9.54 | 10.58 | |
Net Debt/EBITDA |
12.67 | 7.92 | 13.88 | 13.15 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.47 | 0.28 | 0.08 | 0.05 | |
Operating CF/Net income |
(3.71) | 0.93 | 0.84 | 1.02 | |
Capex/Depreciation |
(0.31) | (0.37) | (0.92) | (2.47) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
287.27% | 1,509.49% | 1,046.77% | 534.83% | |
Selling, General and Administrative Expense of Revenue |
71.00% | 378.17% | 241.69% | 113.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
34.18% | 154.94% | 141.31% | 66.57% | |
Graham Net Nets |
0.31 | 0.14 | 0.28 | 0.17 | |
Graham Number |
4.63 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
4.32% | (2.93%) | (9.00%) | (7.27%) | |
Free Cash Flow Yield |
23.75% | (2.11%) | (1.20%) | (1.31%) | |
Revenue per Share |
0.16 | 0.03 | 0.04 | 0.09 | |
Operating CF per Share |
1.22 | (0.52) | (0.37) | (0.43) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.05) | |
Free Cash Flow per Share |
1.21 | (0.53) | (0.39) | (0.48) | |
Cash per Share |
4.75 | 4.54 | 6.67 | 6.12 | |
Shareholders Equity per Share |
2.98 | 2.81 | 5.23 | 4.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.98 | 2.81 | 5.23 | 4.80 | |
Free Cash Flow |
99.78 | (43.78) | (39.24) | (48.84) | |
Working Capital |
340.37 | 328.97 | 606.51 | 571.75 | |
Capital Expenditures |
(0.65) | (0.77) | (1.87) | (4.72) | |
Net Current Asset Value |
187.81 | 177.58 | 463.04 | 427.53 | |
EV/EBIT |
25.77 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.28 | 0.44 | 0.53 | |
Net Profit Margin |
(212.10%) | (1,658.94%) | (1,057.08%) | (483.91%) | |
Price to Operating Income |
71.74 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.78 | 5.89 | 3.01 | 3.65 | |
Average Payables |
9.24 | 10.38 | 7.19 | 6.37 | |
Average Assets |
387.46 | 443.70 | 564.81 | 525.37 | |
Average Common Equity |
225.65 | 228.00 | 398.54 | 377.68 |
Columns are period end dates